How to assess the effectiveness of lipid-lowering medications: Lipid management standards and safety guidelines.

Criteria for Evaluating the Efficacy of Lipid-Lowering Drugs:
Generally, patients with dyslipidemia can evaluate the efficacy of lipid-lowering treatment based on the following aspects to select and adjust their treatment plan.

Regulation of Blood Lipids:
After lifestyle modifications and treatment with lipid-lowering drugs, blood lipid levels should be regularly monitored and compared to determine if target levels have been reached and to assess the efficacy of the treatment. Studies have shown that statins can lower low-density lipoprotein (LDL) by 20%–60% and triglycerides by 7%–30%; fibrates can lower LDL by 5%–20% and triglycerides by 20%–50%.

Reducing the Overall Risk of Cardiovascular Disease:
The purpose of lipid-lowering treatment is not only to regulate lipids but, more importantly, to reduce the risk of coronary heart disease and acute events. Therefore, this aspect should be given more attention when evaluating the efficacy of lipid-lowering treatment. Currently, commonly used statins have a definite effect in preventing and treating coronary heart disease.

Safety:
Understanding the potential side effects of lipid-lowering treatment is crucial. Treatment should undoubtedly utilize methods or drugs with proven efficacy and minimal side effects to avoid serious consequences.

Patient Adherence:
Another important factor in evaluating the efficacy of lipid-lowering treatment is patient adherence. Many patients experience unsatisfactory results because they do not adhere to the treatment, taking the medication inconsistently. Treatment for hyperlipidemia requires long-term treatment to be effective. Drugs like statins can be taken only once a day, but consistent long-term use will yield good results.

Who Should Not Undergo Cholesterol-Lowering Treatment?
(1) Patients with active hepatitis should not use cholesterol-lowering drugs. Because these lipid-lowering drugs are metabolized in the liver, and "all medicines have side effects," taking them can worsen liver damage.
(2) Pregnant or breastfeeding women should not use cholesterol-lowering drugs. Because atherosclerosis is a chronic process, taking lipid-lowering drugs during pregnancy has little impact on the long-term effectiveness of treating primary hypercholesterolemia. Furthermore, cholesterol and other products of its biosynthesis pathway are essential components for fetal development, including the synthesis of steroids and cell membranes. Furthermore, since many medications are secreted into breast milk, and lipid-lowering drugs have potential adverse effects, these medications are not suitable for breastfeeding women.
(3) Lipid-lowering treatment is also not recommended for elderly patients and those with chronic congestive heart failure, dementia, advanced cerebrovascular disease, or active malignant tumors.